Chemical engineering

HealthLynked Corp Announces Chris Hall as New Chief Technology Officer

Retrieved on: 
Tuesday, March 19, 2024
Growth, IBN, New product development, University, Patient, MBA, PMP, ARI, Chemical engineering, Project Management Professional, OTCQB, Colorado State University, Health, Management

NAPLES, Fla., March 19, 2024 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp ( OTCQB: HLYK ), a leader in healthcare technology innovation, is excited to announce Chris Hall as the new Chief Technology Officer (CTO).

Key Points: 
  • NAPLES, Fla., March 19, 2024 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp ( OTCQB: HLYK ), a leader in healthcare technology innovation, is excited to announce Chris Hall as the new Chief Technology Officer (CTO).
  • Chris brings a wealth of experience in technology and product development, marked by his leadership in launching over 100 products and managing diverse, global teams.
  • In his role at HealthLynked, Chris will oversee the company's technology strategy, focusing on the development and coordination of innovative healthcare solutions.
  • Dr. Michael Dent, CEO of HealthLynked, expressed his enthusiasm about Chris's appointment: "Chris joining us marks a transformative step forward.

FuelCell Energy Innovators to Highlight Advanced Clean Technologies at CERAWeek 2024

Retrieved on: 
Tuesday, March 19, 2024
Hydrogen, Mechanical, Hydrogen highway, Engineering physics, Conference, Growth, Physics, FuelCell Energy, Technology policy, H2, James W. Dally, Research, Electrolysis, Interview, Engineering, Leo, Carbon, B cell, Voelker, CO2, Society, Coal, Chemical engineering, Rensselaer Polytechnic Institute, Policy, Renewable energy

Both leaders are members of FuelCell Energy’s InsightFUEL bench of clean energy experts available for interviews with the media.

Key Points: 
  • Both leaders are members of FuelCell Energy’s InsightFUEL bench of clean energy experts available for interviews with the media.
  • Tony Leo joined FuelCell Energy in 1978 and has held key leadership roles in research, development, and commercialization of electrochemical systems during his tenure.
  • The Connecticut Power and Energy Society honored him with its 2023 Excellence in Energy Award.
  • Brent Voelker is Director of Solutions Engineering at FuelCell Energy, responsible for the development of site-level solutions on projects in renewable hydrogen production, long-term energy storage, electric power from renewable hydrogen, and carbon capture.

CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)

Retrieved on: 
Tuesday, March 19, 2024
College, PI3, Data science, Machine, Deep learning, Therapy, Harvard University, Audit trail, Membrane protein, School, Statistics, Biotechnology, ICR, Electrical engineering, Princeton University, 3D, Dartmouth College, Breast cancer, SAB, Applied science, Drug resistance, Royal, Machine learning, Computer science, Drug discovery, Associate, Royal Society, Intelligence, Research, AKT, Cancer, University, Cancer research, DARPA, Howard Hughes Medical Institute, Drug development, Principal, AstraZeneca, Entrepreneurship, The Institute, Biomarker, Columbia University, Faculty, Saint John's College, Stanford University, Chemical engineering, Medicine, Management

LONDON – 19 March 2024 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research company discovering and developing transformational medicines, today announces the foundation of its Scientific Advisory Board (SAB) to provide expert insight and guidance to the Company on the optimal application of 3D deep learning, protein design and prediction in real world medicine.

Key Points: 
  • LONDON – 19 March 2024 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research company discovering and developing transformational medicines, today announces the foundation of its Scientific Advisory Board (SAB) to provide expert insight and guidance to the Company on the optimal application of 3D deep learning, protein design and prediction in real world medicine.
  • This pioneering technology enables CHARM to target and develop treatments for previously hard-to-drug targets in cancer and other therapeutic areas.
  • Laksh Aithani, Co-Founder, Chief Executive Officer and Board Member of CHARM Therapeutics, said: “As CHARM advances its 3D deep learning platform in discovery it’s critical to maintain aligned oversight of our priorities and keep abreast of this emerging field.
  • Founding members of CHARM’s SAB:
    David Baker, Ph.D. is a Scientific Co-Founder at CHARM and Chair of the SAB.

American Rare Earths’ Scoping Study confirms low-cost, scalable world-class REE project

Retrieved on: 
Monday, March 18, 2024
Tetra, Silica gel, Temperature, Mining, Target, ARR, Mineral Resources Limited, Newmont, Filtration, ESG, ASARCO, Thorium, Economic development, ASX, Public expenditure, Environmental quality, Measurement, Molycorp, Stantec, UP, Base case, Society, Competent person, REE, Mineral, Tetra Tech, Engineering, BNSF, IRR, Chemical engineering, NPV, Resource, Allanite, Cowboy, Goldcorp, Metamictisation, Work, Rare-earth element

We note these prices are not sustainable given current prices are at the cash costs of China Northern Rare Earths.

Key Points: 
  • We note these prices are not sustainable given current prices are at the cash costs of China Northern Rare Earths.
  • The inferred Mineral Resource is not the determining factor in determining the viability of the Halleck Creek Rare Earths project.
  • American Rare Earths (ASX: ARR | OTCQX: ARRNF and AMRRY) owns the Halleck Creek, WY and La Paz, AZ rare earth deposits.
  • The Company’s flagship project at Halleck Creek, WY, has the potential to become the largest and most sustainable rare earth projects in North America.

Calibre Strengthens its Team with the Appointment of Vice President, Canadian Operations and Process Plant Manager for the Valentine Gold Mine; Additionally, Calibre Announces GDX Index Inclusion

Retrieved on: 
Monday, March 18, 2024
Lithium, Labrador, Health, Northern College (Ontario), Mining, Metallurgy, Growth, SSR, Chemical engineer, Gold, Lead, Business process management, University, Nemaska Lithium, TSX, CXB, Chemical substance, OTCQX, Iron, Safety, Process, Operation, Chemical engineering, Oil

Additionally, Calibre is pleased to announce that the Company has been added to the VanEck Vectors Gold Miners ETF (NYSE: GDX) (“GDX”).

Key Points: 
  • Additionally, Calibre is pleased to announce that the Company has been added to the VanEck Vectors Gold Miners ETF (NYSE: GDX) (“GDX”).
  • Calibre was added to the GDX Index on March 15, 2024.
  • Darren Hall, President and Chief Executive Officer of Calibre, stated: “I am very pleased to welcome Jason Cyr as the Vice President of Canadian Operations, and André Morneau as Process Plant Manager.
  • We continue to strengthen the team as we focus on operational readiness in preparation for first gold in H1 2025 at the Valentine Gold Mine.

Ibogaine By David Dardashti Explores Chemistry of Treatment for Long Term Opiate Abuse

Retrieved on: 
Friday, March 15, 2024
Ibogaine, DEL, Opioid, Research, Chemical engineering, Medicine, Pharmaceutical industry

PLAYA DEL CARMEN, Mexico, March 14, 2024 (GLOBE NEWSWIRE) -- David Dardashti describes his discovery of ibogaine treatment for long term opiates.

Key Points: 
  • PLAYA DEL CARMEN, Mexico, March 14, 2024 (GLOBE NEWSWIRE) -- David Dardashti describes his discovery of ibogaine treatment for long term opiates.
  • This in turn can lead to a more successful ibogaine treatment when compared to short-term opiate treatments.
  • David discovered an effective combination of medications that can effectively disconnect the neurological pathways created by long-term opiate use, to enable a successful ibogaine treatment prior to the use of ibogaine.
  • Ibogaine By David Dardashti is seeking out qualified clinicians to explore the powerful effects of pure ibogaine hydrochloride on long-term opiate abuse.

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

Retrieved on: 
Wednesday, March 13, 2024
Research, Takeda Pharmaceutical Company, IO, Biotechnology, PFM, University, Patient, Columbia University, Cowen Inc., Doctor of Philosophy, Biochemistry, New Enterprise Associates, CFA, Cancer, Texas A&M University, Pfizer, Chemical engineering, Drug development, NEA, Therapy, ADC, Pharmaceutical industry

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024.

Key Points: 
  • BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024.
  • “We are thrilled to have Santhosh join the Pyxis Oncology board.
  • Santhosh brings a wealth of business, investment, strategic, and board experience to our team,” said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology.
  • "I am delighted to join the Board of Directors at Pyxis Oncology at such a pivotal moment in the Company's journey as they anticipate data readouts for their lead ADC program, PYX-201, and their IO program, PYX-106, in 2024," said Dr. Santhosh Palani.

PanTher Therapeutics Announces Appointment of John Edwards as Executive Chair of the Board of Directors

Retrieved on: 
Friday, April 5, 2024
Oncology, Medical Devices, Health, Surgery, Clinical Trials, Biotechnology, Boston University, Toxicity, Hematology, Genetics, Executive, Monoclonal antibody, Shire (pharmaceutical company), Merck, Acquisition, BMS, Cancer, University, Doctor of Philosophy, Panther, MBA, Marketing, Neoplasm, Therapy, Chemical engineering, Genetics Institute, F-star, FDA, Pharmaceutical industry

PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage oncology company developing high-dose, long lasting, localized treatments for cancer, announced that John Edwards has been appointed as the Executive Chair of the Board of Directors.

Key Points: 
  • PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage oncology company developing high-dose, long lasting, localized treatments for cancer, announced that John Edwards has been appointed as the Executive Chair of the Board of Directors.
  • “John has been an outstanding addition to our Board and management team since joining the company in September.
  • His experience includes involvement with ten FDA approved biologics and eight biotech companies with successful exits, including Tilos Therapeutics, Siamab, Adnexus, F-star and Genetics Institute.
  • During his time as Executive Chair at Tilos, he helped the company from founding to acquisition by Merck in just two years.

Kinetik Announces Changes to Its Board of Directors

Retrieved on: 
Thursday, April 4, 2024
Energy, Other Energy, Oil, Gas, Health, Partner, Natural gas, Audit, Growth, Enterprise Products, KNTK, Retirement, Safety, Chemical engineering, Engineering, Management

Kinetik Holdings Inc. (NYSE: KNTK) (“Kinetik” or the “Company”) announced the appointment of William (“Bill”) Ordemann to the Kinetik Board of Directors, effective April 3, 2024.

Key Points: 
  • Kinetik Holdings Inc. (NYSE: KNTK) (“Kinetik” or the “Company”) announced the appointment of William (“Bill”) Ordemann to the Kinetik Board of Directors, effective April 3, 2024.
  • Additionally, coinciding with Apache’s full exit from its shareholding position in Kinetik, Ben Rodgers resigned from the Board of Directors effective April 3, 2024.
  • Mr. Ordemann will replace Mr. Rodgers, and the Board will continue to consist of eleven independent directors.
  • Ben Rodgers went on to say, “The relationship between Apache and Kinetik will always be unique and special, and I enjoyed the opportunity to serve on the Board of Directors.

Ellie McDonald and Jeannine Sargent Join G2 Venture Partners

Retrieved on: 
Wednesday, April 3, 2024
Environment, Climate Change, Finance, Professional Services, Business, Sustainability, Alternative Energy, Green Technology, Start-Up, Energy, Research, Flex, TEL Solar, Fortive, Growth, Princeton University, Synopsys, MIT, University, Harvard University, Climate, Operations research, Stanford University, MSIP, Investment, Chemical engineering, G2, Engineering, Power, Barclays, Renewable energy

G2 Venture Partners , a venture capital firm investing in transformative technology companies at their inflection points to build a sustainable future, today announced that Ellie McDonald and Jeannine Sargent have joined the firm.

Key Points: 
  • G2 Venture Partners , a venture capital firm investing in transformative technology companies at their inflection points to build a sustainable future, today announced that Ellie McDonald and Jeannine Sargent have joined the firm.
  • Ellie McDonald joins G2 Venture Partners as an Investor, having spent the past seven years working across investment and engineering disciplines.
  • Prior to joining G2, Ellie was a Private Equity Associate at Morgan Stanley Infrastructure Partners (MSIP), primarily investing in the energy and telecommunication sectors.
  • “We are thrilled to welcome the unique perspectives and deep experience that both Ellie and Jeannine bring to our talented team,” said Brook Porter, Founding Partner at G2.